Clinical summary
Summary
This trial will run across two treatment arms. In Treatment Arm 1, eligible patients will receive HDM201 in combination with MBG453. In Treatment Arm 2, patients will receive HDM201 in combination with venetoclax, which will be gradually increased (ramp-up) over a period of 4 to 5 days to achieve the daily target dose tested that will be subsequently continued.Treatment Type
Systemic therapy (chemotherapy, hormone therapy or immunotherapy)Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Novartis Pharmaceuticals
Scientific Title
A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)